Skip to main content
IOVA
NASDAQ Life Sciences

Iovance Q3: Record $121.5M Revenue, Net Loss Narrows to $22.3M, $382.3M Cash

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$8.434
Mkt Cap
$3.941B
52W Low
$1.76
52W High
$15.37
52W Position info
379% above low
Off High info
45% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

IOVA has more than doubled off its 52-week low of $1.76.

Summary

Iovance posted record Q3 product revenue of $121.5M, up 80%, and cut its quarterly net loss to $22.3M while holding $382.3M in cash and investments. The $350M ATM is now fully sold and terminated.


Key Events · Earnings and Guidance · IOVA

  • Record Q3 Revenue of $121.5M

    Total revenue rose 80% to $121.5M from $67.5M, with Amtagvi contributing $101.6M and Proleukin $19.9M.

  • Net Loss Narrows Sharply

    Q3 net loss fell to $22.3M from $91.3M; nine-month loss was $148.6M versus $319.1M, helped by a 34% cut in R&D to $49.3M.

  • Cash of $382.3M, Burn Cut

    Cash, equivalents, short-term investments and restricted cash totaled $382.3M at September 30, 2026; operating cash use fell to $137.4M for nine months from $249.8M.

  • ATM Fully Sold and Terminated

    8,666,654 shares were sold in Q3 at a weighted average of $10.34 for $87.9M net, exhausting the $350M 2025 Sale Agreement, which terminated September 30, 2026.


Analysis · IOVA · Life Sciences

With revenue of $121.5M up 80% year over year and the quarterly net loss shrinking to $22.3M from $91.3M, Iovance is now close to operating breakeven on a much lower expense base. Cash and investments of $382.3M, combined with a burn rate that fell to $137.4M for nine months, give management room to fund the NSCLC and frontline melanoma programs without an immediate raise. The ATM, however, is now fully used up, so the next capital need means a fresh shelf. Whether the $410-420M full-year guidance holds after the mixed October lung-cancer data will drive the stock reaction.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, IOVA was trading at $8.43 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.9B. The 52-week trading range was $1.76 to $15.37. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

IOVA - Latest Insights

IOVA
Nov 05, 2026, 7:00 AM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $9.24
Real-time Price: $7.30 info
Change: -$1.94 (-21%) info
Market Cap: $3.382B info
IOVA
Oct 29, 2026, 5:00 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $9.38
Real-time Price: $7.30 info
Change: -$2.08 (-22%) info
Market Cap: $3.382B info
IOVA
Oct 29, 2026, 3:11 PM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $9.69
Real-time Price: $7.30 info
Change: -$2.39 (-25%) info
Market Cap: $3.382B info
IOVA
Oct 29, 2026, 7:00 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $13.13
Real-time Price: $7.30 info
Change: -$5.83 (-44%) info
Market Cap: $3.382B info
IOVA
Oct 26, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $14.30
Real-time Price: $7.30 info
Change: -$7.00 (-49%) info
Market Cap: $3.382B info